1. Home
  2. PLTK vs SNDX Comparison

PLTK vs SNDX Comparison

Compare PLTK & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Playtika Holding Corp.

PLTK

Playtika Holding Corp.

HOLD

Current Price

$4.08

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$19.20

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLTK
SNDX
Founded
2010
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
PLTK
SNDX
Price
$4.08
$19.20
Analyst Decision
Buy
Strong Buy
Analyst Count
6
13
Target Price
$5.04
$38.69
AVG Volume (30 Days)
1.2M
1.6M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
11.46%
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
$2,755,400,000.00
$172,352,000.00
Revenue This Year
$2.60
$107.19
Revenue Next Year
$2.23
$41.88
P/E Ratio
N/A
N/A
Revenue Growth
8.08
627.84
52 Week Low
$2.64
$12.10
52 Week High
$4.47
$25.59

Technical Indicators

Market Signals
Indicator
PLTK
SNDX
Relative Strength Index (RSI) 58.00 35.86
Support Level $3.33 $16.66
Resistance Level $4.26 $22.40
Average True Range (ATR) 0.24 0.97
MACD 0.00 -0.50
Stochastic Oscillator 72.39 7.34

Price Performance

Historical Comparison
PLTK
SNDX

About PLTK Playtika Holding Corp.

Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. The company offers both Mobile and Web-based platforms.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: